Get the Stockscreener App
0.616
0.65%
0.004
Pre-market:
.60
-0.016
-2.60%
Galmed Pharmaceuticals Ltd stock is traded at $0.616, with a volume of 130.86K.
It is up +0.65% in the last 24 hours and up +2.67% over the past month.
Galmed Pharmaceuticals Ltd is a biopharmaceutical company. The company focuses on the development of Aramchol for combination therapy for GI oncological indications. The company is actively pursuing opportunities in the biotech and medtech spaces to expand and diversify its product pipeline targeting GI, cardiometabolic indications and other product candidates.
See More
Previous Close:
$0.612
Open:
$0.6383
24h Volume:
130.86K
Relative Volume:
0.04
Market Cap:
$4.73M
Revenue:
-
Net Income/Loss:
$-10.31M
P/E Ratio:
-0.2643
EPS:
-2.3308
Net Cash Flow:
$-6.32M
1W Performance:
+31.26%
1M Performance:
+2.67%
6M Performance:
-36.54%
1Y Performance:
-61.50%
1-Day Range:
$0.5851
$0.6383
1-Week Range:
$0.455
$0.6767
52-Week Range:
$0.4111
$2.34
Galmed Pharmaceuticals Ltd Stock (GLMD) Company Profile
Name
Galmed Pharmaceuticals Ltd
Sector
Industry
Phone
-
Address
-
Compare GLMD vs VRTX, REGN, ARGX, ALNY, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
GLMD
Galmed Pharmaceuticals Ltd
|
0.616 | 4.73M | 0 | -10.31M | -6.32M | -2.3308 |
VRTX
Vertex Pharmaceuticals Inc
|
450.46 | 114.33B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
614.98 | 64.47B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
884.20 | 54.99B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
287.80 | 38.42B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
160.06 | 34.03B | 742.00K | -1.37B | -1.07B | -7.0731 |
Galmed Pharmaceuticals Ltd Stock (GLMD) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| May-22-20 | Downgrade | B. Riley FBR | Buy → Neutral |
| Feb-04-20 | Initiated | Craig Hallum | Buy |
| Jan-30-20 | Resumed | Cantor Fitzgerald | Overweight |
| Dec-02-19 | Initiated | Canaccord Genuity | Buy |
| Dec-12-18 | Initiated | B. Riley FBR | Buy |
| Aug-02-18 | Reiterated | Maxim Group | Buy |
| Jul-13-18 | Initiated | Stifel | Buy |
| Jul-12-18 | Initiated | Cantor Fitzgerald | Overweight |
| Jun-12-18 | Reiterated | H.C. Wainwright | Buy |
| Mar-15-18 | Upgrade | Maxim Group | Hold → Buy |
| Feb-14-18 | Downgrade | Maxim Group | Buy → Hold |
| Feb-12-18 | Reiterated | H.C. Wainwright | Buy |
| Nov-15-17 | Initiated | ROTH Capital | Buy |
| Aug-08-17 | Reiterated | H.C. Wainwright | Buy |
| Jul-31-17 | Reiterated | Maxim Group | Buy |
| Aug-01-16 | Reiterated | Maxim Group | Buy |
| Jul-06-16 | Resumed | ROTH Capital | Buy |
| Mar-28-16 | Resumed | H.C. Wainwright | Buy |
| Jun-23-15 | Initiated | H.C. Wainwright | Buy |
| May-06-15 | Initiated | Sun Trust Rbsn Humphrey | Buy |
View All
Galmed Pharmaceuticals Ltd Stock (GLMD) Latest News
GLMD Should I Buy - Intellectia AI
GLMD Q4 2025 Earnings: EPS Misses Estimates by Significant MarginEBITDA Analysis - newsline.com
Galmed to acquire Colospan for USD 4.5M - Medical Buyer
Galmed to acquire medical device firm Colospan for $4.5M By Investing.com - Investing.com Australia
Galmed to Acquire Colospan in Deal Expanding GI Medtech Platform - citybiz
Galmed Pharmaceuticals to Acquire Colospan, targeting $6B GI market - grafa.com
Incyte, Galmed, and Johnson & Johnson Announce Acquisitions Totaling $3 Billion - geneonline.com
Galmed to acquire medical device firm Colospan for $4.5M - Investing.com UK
Galmed Pharmaceuticals to Acquire Colospan and Commit $6 Million to European Expansion - TipRanks
Galmed Pharmaceuticals to Acquire Colospan to Create a GI-Focused Platform Targeting a $6 Billion Market - The AI Journal
Galmed Pharmaceuticals (NASDAQ: GLMD) files amendment adding auditor consent - Stock Titan
Galmed (NASDAQ: GLMD) registers 7.5M shares; agrees to buy Colospan - Stock Titan
[6-K] Galmed Pharmaceuticals Ltd. Current Report (Foreign Issuer) | GLMD SEC FilingForm 6-K - Stock Titan
Press Release: Galmed Pharmaceuticals to Acquire Colospan to Create a GI-Focused Platform Targeting a $6 Billion Market - Moomoo
Galmed’s $6B bet on Colospan device to ease life after colorectal surgery - Stock Titan
GLMD News | GALMED PHARMACEUTICALS LTD (NASDAQ:GLMD) - ChartMill
Galmed and Tissue Dynamics Reveal New Metabolic Target for Cardiac Fibrosis With Aramchol Combo - TipRanks
Galmed, Tissue Dynamics report preclinical cardiac fibrosis data By Investing.com - Investing.com South Africa
Galmed (GLMD) and Tissue Dynamics show fourfold fibrosis cut in human heart organoids - Stock Titan
Galmed, Tissue Dynamics report preclinical cardiac fibrosis data - Investing.com
Tissue Dynamics and Galmed Unveil Unknown Metabolic Pathway for Cardiac Fibrosis and Heart Failure which Supports the Development of Aramchol for Cardiac Fibrosis - PR Newswire
Galmed Pharmaceuticals (GLMD) Surges 9.35% as Shares Test Key ResistanceOutside Reversal - The Legal Advocate
Galmed Pharmaceuticals (GLMD) Surges 9.5%: Testing Key Resistance at $0.71Momentum Trade - The Legal Advocate
GLMD Stock Price, Quote & Chart | GALMED PHARMACEUTICALS LTD (NASDAQ:GLMD) - ChartMill
GLMD Q1'26 Earnings: EPS estimate is (0.38) USD - TradingView
Galmed Pharmaceuticals Ltd expected to post a loss of 38 cents a shareEarnings Preview - TradingView
Number of shareholders of Galmed Pharmaceuticals Ltd. – FWB:GPH - TradingView
Galmed Pharmaceuticals Ltd.Ordinary Shares (NQ: GLMD - FinancialContent
TradingKey - TradingKey
Galmed Reports Fivefold Bioavailability Boost with New Aramchol Meglumine Oral Formulation - TipRanks
Galmed reports improved bioavailability in Aramchol study - Investing.com
Galmed reports improved bioavailability in Aramchol study By Investing.com - Investing.com Australia
Aramchol PK study shows fivefold exposure gain, Galmed (NASDAQ: GLMD) says - Stock Titan
Galmed Announces Results from First-in-Man Pharmacokinetics Study of Oral Formulation of Aramchol Meglumine (AM); 400mg AM Increases Bioavailability by ~500% in Comparison to Aramchol Free Acid (AA) 300mg - PR Newswire
Tissue Dynamics, Galmed partner on cardiac fibrosis model By Investing.com - Investing.com Australia
Tissue Dynamics and Galmed Pharmaceuticals Ltd. (NASDAQ: GLMD) announce a strategic collaboration to jointly develop a chronic cardiac fibrosis research platform focused on human disease models. - Bitget
Galmed (NASDAQ: GLMD) teams with Tissue Dynamics on chronic cardiac fibrosis platform - Stock Titan
Tissue Dynamics, Galmed partner on cardiac fibrosis model - Investing.com
Tissue Dynamics and Galmed Pharmaceuticals to Develop Human-Centered Chronic Cardiac Fibrosis Platform to Advance Aramchol-Based Therapeutics - PR Newswire
GLMD (Galmed Pharmaceuticals Ltd. Ordinary Shares) posts wider than expected Q4 2025 loss, shares dip nearly one percent.Meet Estimates - Xã Thanh Hà
Shmuel Nir Net Worth (2026) - GuruFocus
Amir Poshinski Net Worth (2026) - GuruFocus
Brueck Liat Nissimov Net Worth (2026) - GuruFocus
Doron Leib Cohen Net Worth (2026) - GuruFocus
Allen Baharaff Net Worth (2026) - GuruFocus
Yohai Stenzler Net Worth (2026) - GuruFocus
Guy Nehemya Net Worth (2026) - GuruFocus
Galmed Pharmaceuticals (GLMD) Stock: Beginner's Guide (Smart Money Outflows) 2026-04-15Fast Moving Stocks - Cổng thông tin điện tử Tỉnh Sơn La
Galmed collaborates with Tel Aviv University to evaluate targeted therapy for metastatic brain cancers - BioSpectrum Asia
Galmed Pharmaceuticals Ltd. and Ramot At Tel Aviv University Enter Research Collaboration Agreement - marketscreener.com
Galmed partners with Tel Aviv University on brain cancer therapy By Investing.com - Investing.com Australia
Galmed Pharmaceuticals Ltd Stock (GLMD) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.40%
0.29%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):